Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Belay Birlie YimerRoel BraekersTadesse AwokeAdetayo KasimZiv ShkedyPublished in: BMC infectious diseases (2017)
Moving away from drugs with poor safety profiles, such as stavudine(d4T), could reduce modification rates and this would improve regimen tolerability, while preserving future treatment options.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- end stage renal disease
- hiv aids
- ejection fraction
- hiv infected patients
- chronic kidney disease
- newly diagnosed
- prognostic factors
- hiv testing
- men who have sex with men
- randomized controlled trial
- clinical trial
- current status
- patient reported
- combination therapy